A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients (Q33834630)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients |
scientific article |
Statements
1 reference
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients (English)
1 reference
Taimur Sher
1 reference
Sikander Ailawadhi
1 reference
Kena C Miller
1 reference
Debbie Manfredi
1 reference
Margaret Wood
1 reference
Wei Tan
1 reference
Gregory Wilding
1 reference
Myron S Czuczman
1 reference
Francisco J Hernandez-Ilizaliturri
1 reference
Fredrick Hong
1 reference
Raman Sood
1 reference
Saif Soniwala
1 reference
William Lawrence
1 reference
Saad Jamshed
1 reference
Aisha Masood
1 reference
Daniel Iancu
1 reference
Kelvin Lee
1 reference
Asher Chanan-Khan
1 reference
9 May 2011
1 reference
1 reference
154
1 reference
104-110
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference